Figure 1: Consort diagram; the status of participants in the study
|
|
|
- Melinda Newton
- 5 years ago
- Views:
Transcription
1 Figure : Consort diagram; the status of participants in the study
2 Figure a. Time to first colorectal cancer in those randomized to aspirin compared with those randomized to aspirin placebo (AP). Kaplan-Meier analysis was adjusted for gender. Each point on the plot shows the estimated cumulative incidence by years of follow-up together with the corresponding 95% confidence interval.
3 Figureb. Time to first colorectal cancer in those randomized to aspirin compared with those randomized to the aspirin placebo (AP). In each case, Kaplan-Meier analysis was restricted to participants who had taken years intervention and the analysis was adjusted for gender (HR 4 (CI 9-86), p= ). Each point on the plot shows the estimated cumulative incidence by years of follow-up together with the corresponding 95% confidence interval. 3
4 Figure 3. Time to first Lynch Syndrome cancer in those randomized to aspirin compared with those randomized to the aspirin placebo (AP). In each case, Kaplan- Meier analysis was restricted to participants who had taken years intervention and the analysis was adjusted for gender (HR 45 (CI 6-79), p= 5). Each point on the plot shows the estimated cumulative incidence by years of follow-up together with the corresponding 95% confidence interval. 4
5 Supplementary Tables: Supplementary Table. Study population in detail based on initial randomization to different intervention groups Included in this analysis (n=86 i.e ) Excluded from this analysis Aspirin Aspirin Placebo (AP) Randomised to Resistant Starch (RS) or Resistant Starch Placebo (RSP) only Aspirin and RS 4 RS and AP 8 RS only 4 Aspirin and RSP 4 RSP and AP 6 RSP only 35 Aspirin only 9 AP only Total (937)
6 Supplementary Table : The distribution of Serious Adverse Events by randomization group to aspirin intervention on intervention phase Aspirin N (47) AP N (434) Probable or possible peptic ulcer 7 8 Cerebrovascular events Cardiovascular events 5 Deep Venous thrombosis Major other 4 9 Minor Other including bleeding 5 TOTALS 4 6
7 Supplementary table continued: Detailed breakdown of Serious Adverse Events Abdominal abcess Acute cholecystectitis Anaemia Anal epithelioma Aspergillosis Atrial fibrillation Black stools Bladder stone Bleeding from femoral artery Breast cancer Caecal spirochaetosis Cardiac pain Cellulitis in leg Cerebral haemorrhage Cerebral vasculitis Coronary arterial stenosis Coronary thrombosis Died (before receiving therapy) Duodenal ulcers 3 3 Deep venous thrombosis Endophlebitis Failure of anal stoma repair to heal Gastric ulcer Gastritis Gastrointestinal bleed Gum bleeding Hernia with gastric reflux Hip replacement Liver cancer Lung sarcoidosis Malignant melanoma Meningioma brain tumour Myocardial infarction Numbness on one side of body Operation to close abdominal jejunostomy Pancreatic cyst Hysterectomy Pre-tracheal lymphoma Prostate cancer Pyelonephritis Rectal bleed 7
8 Severe nose bleed Spinal canal stenosis Stroke Testicular mass Vaginal bleeding Ventricular fibrillation 8
9 Supplementary Table 3. Demographic details for those with follow-up information showing time on study in months Participants with further long-term follow up data Participants without long-term follow up data Number of participants Time on CAPP intervention study mean (sd) (range) -3 months 4-47 months 48+ months 7 (3 ) (, 74 4) 86 (7 7%) 395 (58 9%) 9 (3 4%) 8 6 ( 9) ( 8, 6 6) 5 (6 6%) 66 (34 7%) 9 (4 7%) Total 5. (3 4) ( 8,74 4) 3 (35 %) 46 (53 5%) 99 ( 5%) Time since study entry mean (sd)(range) 66 (6 8) ( 5, 8) 8 6 ( 9) ( 8, 6 6) 55 7 (3 4) ( 8,8) -3 months 8 (4 %) 7 (6 6%) 45 (6 8%) 4-47 months 3 (8 3%) 64 (33 7%) 87 ( 7%) months 6 (8 8%) 8 (4 %) 34 (5 6%) 6+ months 394 (58 7%) ( 5%) 395 (45 9%) Age at recruitment mean (sd)(range) 44 7 ( 6) (4 7, 75 5) 43 ( 7) ( 5, 77 9) 44 3( 6) ( 5,77 9) -36 years 59 (3 7%) 56 (9 5%) 5 (5%) years 66 (4 8%) 49 (5 8%) 5 (5%) years 7 (5 3%) 45 (3 7%) 5 (5%) years 76 (6 %) 4 ( %) 6 (5%) 9
10 Supplementary Table 4. Number of years until first colorectal cancer diagnoses by years since randomization for those with a CRC diagnosis Years Since randomization Randomized to aspirin (N=47) Randomized to AP (N=434) Randomized to RS or RSP only (N=76)* Total * This group was not included in the analysis for this study.
11 Supplementary Table 5. Distribution of Lynch Syndrome related cancers Randomized to aspirin (N=47) Randomized to AP (N=434) Randomized to RS or RSP only (N=76)* Participants with cancer attributed to Lynch Syndrome Colorectal cancer Total Other Lynch Syndrome cancers: - Endometrial - Pancreas - Ureter - Brain - Small Bowel - Gastric - Cholangiocarcinoma - Kidney - Ovarian TOTAL * This group was not included in the analysis for this study.
12 Supplementary Table 6 CRC by participants molecular diagnosis Gene Status CRC not detected CRC diagnoses* Total N(%) N(%) Clinical diagnosis 56 (96) 7 (4) 63 MSH mutation carrier 64 (93) (7) 84 MLH mutation carrier 436 (94) 8 (6) 464 MSH6 mutation carrier 6 () () 6 Total 883 (94) 55 (6) 937 *Includes 7 cases with CRC randomized to RS or RSP only
13 Supplementary figure. Kaplan-Meier function of time to first non-crc Lynch syndrome cancer comparing those randomized to aspirin with those randomized to aspirin placebo (AP) adjusted for gender. Each point on the plot shows the estimated cumulative incidence by years of follow-up together with the corresponding 95% confidence interval. 3
14 4
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL
MAIN OFFICE: (618) 692-7478 MORGUE: (618) 296-4525 FAX: (618) 692-6042 FAX: (618) 692-9304 STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL. 62025-1962
Mr Chris Wakeman. General Surgeon University of Otago, Christchurch. 12:15-12:40 Management of Colorectal Cancer
Mr Chris Wakeman General Surgeon University of Otago, Christchurch 12:15-12:40 Management of Colorectal Cancer Bowel cancer Chris Wakeman Colorectal Surgeon Christchurch Sam Simon (Simpsons) Elizabeth
List of Qualifying Conditions
List of Qualifying Conditions Cancer Conditions 1) Adrenal cancer 2) Bladder cancer 3) Bone cancer all forms 4) Brain cancer 5) Breast cancer 6) Cervical cancer 7) Colon cancer 8) Colorectal cancer 9)
Supplementary Online Content
Supplementary Online Content Guimarães PO, Krishnamoorthy A, Kaltenbach LA, et al. Accuracy of medical claims for identifying cardiovascular and bleeding events after myocardial infarction: a secondary
Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy?
Is aspirin ready for colorectal cancer chemoprevention and adjuvant therapy? Robert Benamouzig Service de Gastroentérologie Hôpital Avicenne Bobigny, France Aspirin and Colorectal carcinogenesis Aspirin
Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions
Protocols 9-12 MMR mutation carrier guidelines Frequently asked questions Last updated: 10/02/2015 Q: Where have the general population cancer risks been taken from? The risk figures for the general population
Patient Name Date of Birth Age. Other phone ( ) . Other
GASTROINTESTINAL & MINIMALLY INVASIVE SURGERY HEALTH HISTORY QUESTIONNAIRE Date Patient Name _ Date of Birth Age Daytime phone ( ) Other phone ( ) Email How did you hear about us? My doctor Yellow pages
Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care AF symptoms Tachycardia
Supplementary Table S1 International Classification of Disease 10 (ICD-10) codes Comorbidity or medical history Existing diagnoses between 1 January 2007 and 31 December 2011 AF management care I48 AF
PLEASE COMPLETE ALL SECTIONS OF THIS FORM
PLEASE COMPLETE ALL SECTIONS OF THIS FORM Patient Name: Date of Birth: Referring Doctor? (Name, telephone number and address) Chief Complaint: Why have you come here? How did it start? What are the symptoms?
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health
J. Van Lier Ribbink, M.D., F.A.C.S. Center for Endocrine and Pancreas Surgery at Honor Health Patient Clinical Information Questionnaire 1.0 Date of Questionnaire Completion; / / 2.0 Patient Data 2.1 Name:
Patient Interview Form
Patient Interview Form Patient Information First Name: MRN: Age: Last Name: Date Of Birth: tes: Contact Preference Email Telephone call/leave message Patient declines to specify Email Please check one
SUPPLEMENTAL DIGITAL CONTENT 2 : SURGERY SUBGROUPS DEFINITONS AND DISTRIBUTION
mortality 24h in ICU mortality 24h in ICU 1 SUPPLEMETAL DIGITAL COTET 2 : SURGERY SUBGROUPS DEFIITOS AD DISTRIBUTIO =2,717,902 GHM codes* Surgery description CARDIAC SURGERY 05C021 to 05C034 Cardiac valve(s)
SUPPLEMENTARY MATERIAL
SUPPLEMENTARY MATERIAL Deep Patient: An Unsupervised Representation to Predict the Future of Patients from the Electronic Health Records Riccardo Miotto 1,2, Li Li 1,2, Brian A. Kidd 1,2, and Joel T. Dudley
PHA Annual High Claims Report 2018
24 October 2018 Medical device costs, increasing complexity and growing numbers of long hospital stays for mental health problems drive high health insurance claims PHA s Annual High Claims 2018 Report
Laser Vein Center Thomas Wright MD Page 1 of 4
Demographics Laser Vein Center Thomas Wright MD Page 1 of 4 Patient Name: Address: City, St, Zip Primary Phone: Alternate: DOB: Social Security #: Insurance Information Primary Insurance ID# Group# Subscriber
Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture
Technical Appendix Table S1: Diagnosis and Procedure Codes Used to Ascertain Incident Hip Fracture and Associated Surgical Treatment ICD 9 Code Descriptions Hip Fracture 820.XX Fracture neck of femur 821.XX
New Patient Medical History Form
New Patient Medical History Form Date: Name: Date of Birth: Address: City: ZIP: Home Phone #: Cell Phone #: Emergency Contact: Relationship: Emergency Contact Phone #: Primary Care Physician: Referring
Arteriovenostomy for renal dialysis 39.27, 39.42
Surgery categories NHSN Surgery codes (Reference: NHSN Operative Procedure Category Mappings to ICD-9-CM Codes, October 2010 www.cdc.gov/nhsn/pdfs/pscmanual/9pscssicurrent.pdf) Operative aortic aneurysm
Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene)
EMA/679870/2014 Summary of the risk management plan (RMP) for Duavive (conjugated oestrogens / bazedoxifene) This is a summary of the risk management plan (RMP) for Duavive, which details the measures
Breast Cancer Prevention for the Population at Large
Breast Cancer Prevention for the Population at Large Jack Cuzick Centre for Cancer Prevention Wolfson Institute of Preventive Medicine St Bartholomew s Medical School Queen Mary University of London London,
Hereditary Cancer Products
Hereditary Products Integrated BRACAnalysis (BRCA1 and BRCA2 sequencing and large rearrangement testing (BART)), covered when: PERSONAL HISTORY of Breast (must meet at least 1) Diagnosed
Safe Answers For The American Board of Surgery Certifying Exam & Recertifying Exam
Safe Answers For The American Board of Surgery Certifying Exam & Recertifying Exam By Sarmad Aji, MD., FACS. A comprehensive review of the most commonly asked questions on the American Board of Surgery
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE. Cranial Health History Form
WASHINGTON UNIVERSITY SCHOOL OF MEDICINE Cranial Health History Form Welcome to the Neurosurgery Department at Washington University. To help us treat you, please fill this form out completely. Your Name:
Full Novartis CTRD Results Template
Full Novartis CTRD Results Template Sponsor Novartis Generic Drug Name vildagliptin Therapeutic Area of Trial Type 2 diabetes Approved Indication Type 2 diabetes Protocol Number CLAF237A23138E1 Title A
Appendix Criteria used for the automated chart review
Appendix Criteria used for the automated chart review A. Heart attack i. 410.01 (Acute myocardial infarction of anterolateral wall initial episode of ii. 410.11 (Acute myocardial infarction of other anterior
NAME DATE Page 1. Other. Kidney Removed (Right, Left) Bladder Removed. Ovaries Removed for Endometriosis Breast Biopsy
NAME DATE Page 1 Past Medical History: (please circle ALL that apply) Anxiety Hepatitis Arthritis Hypertension Artificial joints HIV/AIDS Asthma Hypercholesterolemia Atrial fibrillation Hyperthyroidism
Supplement materials:
Supplement materials: Table S1: ICD-9 codes used to define prevalent comorbid conditions and incident conditions Comorbid condition ICD-9 code Hypertension 401-405 Diabetes mellitus 250.x Myocardial infarction
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer
GYNplus: A Genetic Test for Hereditary Ovarian and/or Uterine Cancer Causes of Hereditary Ovarian and Uterine Cancer uterine cancer ovarian cancer Sporadic 75-90% Sporadic 70-80% Hereditary, 5% Lynch syndrome
STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL
MAIN OFFICE: (618) 692-7478 MORGUE: (618) 296-4525 FAX: (618) 692-6042 FAX: (618) 692-9304 STEPHEN P. NONN OFFICE OF THE CORONER MADISON COUNTY, ILLINOIS 157 MAIN STREET SUITE 354 EDWARDSVILLE, IL. 62025-1962
Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager
Why is co-morbidity important for cancer patients? Michael Chapman Research Programme Manager Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient in addition
PREAMBLE GENERAL DIAGNOSTIC RADIOLOGY
PREAMBLE The General Diagnostic Radiology category is intended to cover the body of knowledge a practicing board certified Diagnostic Radiologist should know. Since the range of content relevant to the
Spleen indications of splenectomy complications OPSI
Intestinal obstruction Differences between adynamic ileus and mechanical obstruction Aetiology Pathophysiology (Cluster contractions- bowel proximal to the obstruction dilate- wall of obstructed gut is
PATIENT INFORMATION. Are we currently seeing one of your family members at our practice, or have we previously? YES patient s name:
PATIENT INFORMATION Date Name Address First Middle Last City State Zip Home # Cell # Check this box to authorize text messaging for confirming and reminders Email Check this box to authorize our office
Episodes of Care Risk Adjustment
Episodes of Care Risk Adjustment Episode Types Wave 1 Asthma Acute Exacerbation Perinatal Total Joint Replacement Wave 2 Acute Percutaneous Coronary Intervention COPD Acute Exacerbation Non-acute Percutaneous
532.6 (chronic or unspecified duodenal
Supplementary table 1: ICD-9 and ICD-10 codes used for the identification of major bleeding and endoscopy Bleeding episode type ICD-9 codes ICD-10 codes Intracranial 430 (Subarachnoid), 431 (intracerebral),
Providence Medical Group
Providence Medical Group To our valued patients: In order to provide you with our full attention when you come for an appointment, we would like to ask you to be aware of the following guidelines. Insurance
PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...
Table of contents Summary tables PERSONAL CHARACTERISTICS AND REPRODUCTIVE HISTORY...3 Pregnancy...3 Age...3 Parity...3 Breastfeeding...3 Postpartum...3 Post-abortion...3 Past ectopic pregnancy...3 History
APR-DRG Description Ave Charge
Abdominal Pain 16,500.25 2.8 6,000.09 Acute & Subacute Endocarditis 15,339.30 3.0 5,113.10 Acute Myocardial Infarction 17,687.46 2.6 6,802.87 Alcohol Abuse & Dependence 19,126.64 4.2 4,553.96 Alcoholic
Supplementary Online Content
Supplementary Online Content Tran AH, Ngor EWM, Wu BU. Surveillance colonoscopy in elderly patients: a retrospective cohort study. JAMA Intern Med. Published online August 11, 2014. doi:10.1001/jamainternmed.2014.3746
Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme
Why is co-morbidity important for cancer patients? Di Riley Associate Director Clinical Outcomes Programme Co-morbidity in cancer Definition:- Co-morbidity is a disease or illness affecting a cancer patient
5.2 Main causes of death Brighton & Hove JSNA 2013
Why is this issue important? We need to know how many people are born and die each year and the main causes of their deaths in order to have well-functioning health s. 1 Key outcomes Mortality rate from
Content. Diagnostic approach and clinical management of Lynch Syndrome: guidelines. Terminology. Identification of Lynch Syndrome
of Lynch Syndrome: guidelines 17/03/2009 Content Terminology Lynch Syndrome Presumed Lynch Syndrome Familial Colorectal Cancer Identification of Lynch Syndrome Amsterdam II criteria Revised Bethesda Guidelines
Laser Vein Center Thomas Wright MD RVT Page 1 of 4
Demographics Laser Vein Center Thomas Wright MD RVT Page 1 of 4 Patient Name: Address: City, St, Zip Primary Phone: Alternate: DOB: Social Security #: Marital Status: Married Single Other Emergency Contact:
Ticagrelor compared with clopidogrel in patients with acute coronary syndromes the PLATO trial
compared with clopidogrel in patients with acute coronary syndromes the PLATO trial August 30, 2009 at 08.00 CET PLATO background In NSTE-ACS and STEMI, current guidelines recommend 12 months aspirin and
Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation
Ontario s Referral and Listing Criteria for Adult Pancreas-After- Kidney Transplantation Version 2.0 Trillium Gift of Life Network Adult Pancreas-After-Kidney Transplantation Referral & Listing Criteria
Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives:
The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product.
GI Screening/Surveillance in Lynch Syndrome
GI Screening/Surveillance in Lynch Syndrome M Appleyard Royal Brisbane and Women s Hospital Brisbane, Australia GI Disease and Lynch Syndrome What are risks of GI disease in Lynch? Who do we screen for
PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS:
1 NAME: DATE OF BIRTH PLEASE LET US KNOW YOUR REASON FOR TODAY S VISIT : CURRENT MEDICATIONS (WITH DOSAGE) PLEASE INCLUDE VITAMINS AND HERBAL MEDICATIONS: PAST MEDICAL HISTORY (YOUR MEDICAL HISTORY) :
Patient Name Date of Birth MALE / FEMALE Date. Left handed or Right handed. Marital Status: Single Married Divorced Widowed Children?
PH NEW PATIENT HISTORY Patient Name Date of Birth MALE / FEMALE Date Occupation: Left handed or Right handed Marital Status: Single Married Divorced Widowed Children? Y or N # Previous Treating Physician:
TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM
TEXAS VASCULAR ASSOCIATES, P.A. PATIENT CLINICAL INTAKE FORM PATIENT NAME: DATE OF BIRTH: TVA Physician being seen: Date of Visit: PAST MEDICAL HISTORY HEART PROBLEMS NEUROLOGICAL Congestive Heart Failure
DRG Code DRG Description FY18 Average Charge
DRG Code DRG Description FY18 Average Charge 3 ECMO OR TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W MAJ O $ 665,511 4 TRACH W MV 96+ HRS OR PDX EXC FACE, MOUTH & NECK W/O MAJ O.R. $ 422,497 37 EXTRACRANIAL
How much do you know about illnesses or health problems for your parents, grandparents, brothers, sisters, and/or children? 1 A lot Some None at all
Family Health History Please answer each question as honestly as possible. There are no right or wrong answers to nay of the questions. It is important that you answer as many questions as you can. We
Patient Interview Form
Patient Interview Form Patient Information First Name: Date Of Birth: Last Name: Email Please check one as your preferred email for communications Personal: Work: Race Select one or more White Unknown
AUTHORIZATION TO RELEASE AND/OR OBTAIN PATIENT INFORMATION
Medical Record # Patient Name(s) Date of Birth Social Security # Contact Phone # AUTHORIZATION TO RELEASE AND/OR OBTAIN PATIENT INFORMATION OBTAIN FROM: (Releasing facility) RELEASE TO: (Receiving entity)
BowelGene. How do I know if I am at risk? Families with hereditary bowel cancer generally show one or more of the following clues:
BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK. Unfortunately 1 in 19 women and 1 in 14 men will develop
Primary Care Approach to Genetic Cancer Syndromes
Primary Care Approach to Genetic Cancer Syndromes Jason M. Goldman, MD, FACP FAU School of Medicine Syndromes Hereditary Breast and Ovarian Cancer (HBOC) Hereditary Nonpolyposis Colorectal Cancer (HNPCC)
Prevention of Bowel Cancer: which patients do I send for colonoscopy?
Prevention of Bowel Cancer: which patients do I send for colonoscopy? Dr Chris Groves Consultant Gastroenterologist and Honorary Senior Lecturer St George s Hospital and Medical School Director, SW London
Surgical Workload, Outcome and Research Database: V1.1
Technical Guidance for Surgical Workload, Outcome and Research Database: V1.1 Contents 1. Standard Indicators... 5 1.1. Activity Volume... 5 1.2. Average Length of Stay (Days)... 5 1.3. 2/7/30 day Re-admission
Please describe your reason for today s visit: What are you hoping to get out of today s visit? How long has this been going on?
Date of Birth: Name: Patient History Form Reason for Visit Please describe your reason for today s visit: What are you hoping to get out of today s visit? How long has this been going on? Does anything
Patient Interview Form
Page 1 of 5 Patient Interview Form Patient Information First Name: Date Of Birth: Last Name: Age: Email Please check one as your preferred email for communications Personal: Work: Race Select one or more
Chapter Goal. Learning Objectives 9/12/2012. Chapter 29. Nontraumatic Abdominal Injuries
Chapter 29 Nontraumatic Abdominal Injuries Chapter Goal Use assessment findings to formulate field impression & implement treatment plan for patients with nontraumatic abdominal pain Learning Objectives
Preferred Pharmacy. Past Medical History
Name: Date: Street Address: City / State: Zip Code: Date of Birth: Gender: Phone Number (day): Phone Number (evening): Email Address: Emergency Contact: Preferred Pharmacy Name: Phone Number: City and
GYNplus. genetic testing for hereditary ovarian and/or uterine cancer
GYNplus genetic testing for hereditary ovarian and/or uterine cancer What Are the Causes of Hereditary Ovarian and Uterine Cancer? uterine cancer ovarian cancer sporadic 70-80% hereditary 5% Lynch syndrome
Selected tables standardised to Segi population
Selected tables standardised to Segi population LIST OF TABLES Table 4.2S: Selected causes of death, all-ages, 2000 2004 (Segi Standard) Table 5.3S: Public hospitalisations by major cause of admission
PATIENT INFORMATION (Please print all information) Date:
320 Lillington Ave Suite 101 Charlotte, NC 28204-3189 Phone: 704.362.4403 Fax: 704.362.4405 Please fill out the following form completely so that we may obtain the necessary information for our files and
Supplementary appendix
Supplementary appendix This appendix formed part of the original submission and has been peer reviewed. We post it as supplied by the authors. Supplement to: Williams CM, Maher CG, Latimer J, et al. Efficacy
GHUK BowelGene_2017.qxp_Layout 1 22/02/ :22 Page 3 BowelGene
GHUK BowelGene_2017.qxp_Layout 1 22/02/2017 10:22 Page 3 BowelGene BowelGene What is hereditary bowel cancer? Bowel cancer (also known as colorectal cancer) is the fourth most common cancer in the UK.
ANY FAMILY HISTORY OF ANEURYSM OR DVT?
NAME: D/O/B: DATE: MR# WHAT PROBLEM(S) BRINGS YOU HERE TODAY? WHO SENT YOU TO US? DOCTOR/OTHER WHICH DOCTOR? WHAT SURGERY HAVE YOU HAD AND WHEN? (LIST) 1. 2. 3. 4. 5. 6. 7. HOW MUCH ALCOHOL DO YOU DRINK
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert.
PFIZER INC. These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert. PROPRIETARY DRUG NAME / GENERIC DRUG NAME: Inspra / Eplerenone
lnhs BLOOD AND TRANSPLANT RESEARCH, INNOVATION AND NOVEL TECHNOLOGIES ADVISORY GROUP DCD HEART ACTIVITY
lnhs BLOOD AND TRANSPLANT RESEARCH, INNOVATION AND NOVEL TECHNOLOGIES ADVISORY GROUP INTRODUCTION DCD HEART ACTIVITY 1 DCD heart retrieval began in February 2015 for a 15 month initial evaluation period
Myriad Financial Assistance Program (MFAP)
Myriad Financial Assistance Program (MFAP) MEDICAL CRITERIA Hereditary Cancer Products The Myriad Financial Assistance Program offers aid to patients who meet specific financial and medical requirements.
Ontario s Referral and Listing Criteria for Adult Kidney Transplantation
Ontario s Referral and Listing Criteria for Adult Kidney Transplantation Version 3.0 Trillium Gift of Life Network Adult Kidney Transplantation Referral & Listing Criteria PATIENT REFERRAL CRITERIA: The
Examination: Type of examination: Description of the examination Price:
Examination: Type of examination: Description of the examination Price: Ultrasound / Sonographic examination/ Ultrasound examination of the upper abdominal area It is an examination of the liver, bile
Lynch Syndrome. Angie Strang, PGY2
Lynch Syndrome Angie Strang, PGY2 Background Previously hereditary nonpolyposis colorectal cancer Autosomal dominant inherited cancer susceptibility syndrome Caused by defects in the mismatch repair system
Bladder and genitourinary tumours
Oxford Scholarship Online You are looking at 2751-2760 of 3042 items for: keywords : stasis pubepi Bladder and genitourinary tumours Claudio Pelucchi and Carlotta Galeone Published in print: Published
HORMONE REPLACEMENT THERAPY
TRIALS OF HR RUTH (Barrett- Connor et al 29 ) JULY 2006 (Country) mean ± sd, range International trial 67.5 an Placebo component in 67.5 ± 6.7 women with Raloxifene or multiple 67.5 ± 6.6 risk factors
o Kidney Cancer o Liver Cancer o Tremor o Tuberculosis o B12 Deficiency o Esophageal Cancer o Liver Disease o Pituitary Tumor o Uterine o Neurological
Adult New Patient Registration PATIENT DOB: / / MONTH DAY YEAR PATIENT NAME: LAST FIRST MI o Abnormal Heartbeat Patient Medical History: Please mark all that apply o Chronic Headaches o Hepatitis C o Neuropathy
Maine Workers' Compensation Board Medical Fee Schedule
001 SURG HEART TRANSPLANT OR IMPLANT OF HEART ASSIST SYSTEM W MCC 29.1 26.4106 $243,431.25 $257,869.40 002 SURG SYSTEM W/O MCC 15.1 13.4227 $123,719.44 $131,057.36 003 SURG MOUTH & NECK W MAJ O.R. 23.4
Supplementary Online Content
Supplementary Online Content Chacón MR, Enrico DH, Burton J, Waisberg FD, Videla VM. Incidence of placebo adverse events in randomized clinical trials of targeted and immunotherapy cancer drugs in the
Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code:
Patient Information Last Name: First Name: Middle Initial: Address: City: State: Zip Code: Date of Birth (MM/DD/YY): Social Security #: Sex: Male Female Home Phone #: Mobile Phone #: Email Address: Marital
City State Zip. Cell Phone. Other Phone. Gender Male Female Status Single Married Divorced Widowed. Height Weight EXERCISE Yes No Times per Week
Patient Name (First Middle Last) Date of Birth Social Security # Address City State Zip Home Phone Work Phone Cell Phone Other Phone Email Place of Birth Occupation Retired Yes No Gender Male Female Status
Southwest Service Life Insurance Company
Southwest Service Life Insurance Company UNDERWRITING GUIDE 2/2012 95587v1Proof.indd 1 95587v1Proof.indd 2 95587v1Proof.indd 3 Acne A A A ADD A A A Addison s Disease D A D AIDS, ARC, HIV Infection D D
San Luis Dermatology & Laser Clinic, Inc.
San Luis Dermatology & Laser Clinic, Inc. Patient Name: Pharmacy Name: Primary Care physician: LOCATION City: Health History Intake Form The federal government has defined a complete electronic medical
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
MLH1 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MLH1 Summary Cancer Risk Table
MLH1 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Cancer (HNPCC) MLH1 Summary Cancer Risk Table CANCER GENETIC CANCER RISK Endometrial Other MLH1 gene Overview Lynch syndrome 1,
Clinical indications for positron emission tomography
Clinical indications for positron emission tomography Oncology applications Brain and spinal cord Parotid Suspected tumour recurrence when anatomical imaging is difficult or equivocal and management will
Stroke / CVA TIA Trauma Dizziness Headaches. Acoustic Neuroma Syrinx Visual Change Vascular Lesions (AVM) Elevated Prolactin Vertigo Bell s palsy
Head Brain Alzheimer s Mental Status Change Confusion Dementia Memory Loss Dizziness Headaches MRI Brain w/o 70551 Tumor / Mass / Cancer Cranial Nerve Lesions HIV Infection Suspected MS Neurofibromatosis
Medication Allergies
**PLEASE CHECK IN 15 MINUTES PRIOR TO APPOINTMENT WITH FORMS COMPLETED** Primary Provider at Ocotillo Internal Medicine Other Physicians you see: Jonathan Hackenyos, D.O. 1. Cheryl Maurice, M.D. 2. 3.
S2 File. Clinical Classifications Software (CCS). The CCS is a
S2 File. Clinical Classifications Software (CCS). The CCS is a diagnosis categorization scheme based on the ICD-9-CM that aggregates all diagnosis codes into 262 mutually exclusive, clinically homogeneous
Form C KNHSS Operative Procedure Categories Codes
Form C KNHSS Operative Procedure Categories Codes NHSN Operative Procedure Category Mappings to ICD-9-CM Codes and CPT Codes CPT codes are to be used for outpatient surgery cases only. KNHSS Code NHSN
Supplementary Appendix
Supplementary Appendix This appendix has been provided by the authors to give readers additional information about their work. Supplement to: Solomon SD, Uno H, Lewis EF, et al. Erythropoietic response
MSH6 gene. Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table
MSH6 gene Associated Syndrome Name: Lynch syndrome/hereditary NonPolyposis Colorectal Cancer (HNPCC) MSH6 Summary Cancer Risk Table CANCER Colorectal GENETIC CANCER RISK High Risk Endometrial High Risk
Risk of Colorectal Cancer (CRC) Hereditary Syndromes in GI Cancer GENETIC MALPRACTICE
Identifying the Patient at Risk for an Inherited Syndrome Sapna Syngal, MD, MPH, FACG Director, Gastroenterology Director, Familial GI Program Dana-Farber/Brigham and Women s Cancer Center Associate Professor
Health History Intake Form;
Health History Intake Form; Today s Date: Patient Name: Date of Birth: Age: Previous Primary Care Physician (if any): Phone: Address: Other Physicians involved in your care: Reason for visit today: Allergies
PATIENT INFORMATION Please print clearly and complete all blanks
PATIENT INFORMATION Please print clearly and complete all blanks DATE: REFERRED BY: SEX: NAME: LAST FIRST MIDDLE BIRTHDATE: MAILING ADDRESS: CITY STATE ZIP TELEPHONE: CELL PHONE: WORK NUMBER: SS # MARITAL
What is Laparoscopy All About?
Disclaimer This movie is an educational resource only and should not be used to manage surgical health. All decisions about the management of Laparoscopy must be made in conjunction with your Physician
Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies
Web appendix 2: SEARCH STRATEGIES Interventions for non-metastatic squamous cell carcinoma of the skin: a systematic review and pooled analysis of observational studies MEDLINE 1. exp epidemiologic studies/